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Sickle cell disease (SCD) or sickle cell anemia (SCA) is an
inherited disorder of hemoglobin (Hb) caused by substitution
of a single nucleotide from thymine to adenine (GAGﬁ GTG)
in the b-chain of hemoglobin resulting in amino acid valine
instead of glutamic acid (Rees et al., 2010). This point muta-
tion is responsible for alteration in the properties of the
hemoglobin tetramer, with a tendency to polymerize in the
deoxygenated state (Ballas, 2002), altering normal, ﬂexible
biconcave shaped red blood cells (RBCs) into stiff, rigid, sickle
cell. The rate of polymerization of Sickle cell hemoglobin
(HbS) is directly related to fundamental pathophysiology of
hemolytic anemia and vaso-occlusion (Samuel et al., 1990).
1.1. Biomarkers in SCD
The Biomarkers Deﬁnitions Working Group has deﬁned a
‘‘biomarker’’ as a ‘‘characteristic that is objectively measured
and evaluated as an indicator of normal biological or patho-
genic processes, or pharmacological responses to a therapeutic
intervention’’ (Biomarkers Deﬁnitions Working Group, 2001).There is high variability in terms of severity of SCD. Different
major complications of SCD such as acute chest syndrome
(Vichinsky et al., 2000), cerebrovascular disease (Ohene-
Frempong et al., 1998), kidney failure (Scheinman, 2009) and
early deaths (Platt et al., 1994) lead to variability in
biomarkers.
Meaningful markers therefore have prime importance in
the management of this disease. In this review, we will focus
on the analysis of body ﬂuids and tissues that have prime
importance in the management of SCD. DNA markers
(Steinberg and Adewoye, 2006) and imaging biomarkers will
not be discussed in this review although they have been shown
to be beneﬁcial in the management of SCD (Adams et al.,
1998).
1.2. Biomarkers used for HbS polymerization
Polymerization of the deoxygenated HbS is the leading phe-
nomenon contributing to SCD related medical problems.
The polymerization initiation rate is directly proportional to
quantity of deoxygenated HbS within the RBC. Currently such
biomarkers which can directly measure HbS polymerization
Table 1 Effect of a-thalassemia on some clinical complications of sickle cell anemia (adapted from Steinberg, 2009).
Sickle cell disease phenotype Eﬀect of a-thalassemia
Protectivea Permissiveb Unrelated Probably little eﬀect
Survival +  – 
Painful episodes  +  
Stroke +   
Osteonecrosis  +  
Acute chest syndrome   + 
Cholelithiasis +   
Leg ulcer +   
Splenic function +   
Growth and development   + 
Menarche +  
Priapism  +  
Splenic sequestration    +
HbF    +
a ‘‘Protective’’ denotes a reduction in the incidence or prevalence of a phenotype with a-thalassemia.
b ‘‘Permissive’’ denotes an increased incidence or prevalence of a phenotype when a-thalassemia is present.
26 G.A. Damanhouri et al.rate in RBCs do not exist. It is not clear whether any direct
relation exists between SCD phenotypic diversity and different
rates of HbS polymerization (Vekilov, 2007). Fetal hemoglo-
bin (HbF) and a-thalassemia are the two well-studied
biomarkers in SCD, capable of changing the intracellular con-
centrations of HbS that ultimately dictate the pace and extent
of polymerization.
1.2.1. HbF
HbF is different from the adult hemoglobin due to the higher
afﬁnity of HbF to bind oxygen, hence providing the growing
fetus with better access to oxygen from the mother’s blood-
stream. It has been shown clinically that cells containing
HbF survive longer than cells with HbS (Charache, 1990).
Polymerization of HbS is the pivotal step in the pathophysiol-
ogy of SCD but elevated levels of HbF have been shown to
halt this process (Franco et al., 2006; Lanzkron et al., 2008) .
Furthermore, due to its inability to enter the HbS-polymeriza-
tion phase, HbF can be regarded as the pivotal regulator of the
clinical and hematologic features of SCD (Rees and Gibson,
2012). Moreover, Sebastiani et al. have deﬁned the ‘‘HbSF’’
phenotype as the HbF concentration of 10% or more in
SCD patients who are aged four or above because this is the
age at which levels of HbF become stable (Sebastiani et al.,
2010).
Level of expression of HbF varies in different variants of
sickle erythrocytes, of which Saudi-Indian and Senegal haplo-
type of HBB-like gene cluster (Homozygous for Glu6Val in
b-globin gene) have the highest levels. Levels of HbF differ in
other variants of SCD. In terms of the prevalence of SCD in
Saudi Arabia, mostly individuals from the Eastern Province
are the carriers of the Saudi-Indian b-globin gene-like cluster
haplotype with elevated levels of HbF, and a milder clinical
manifestation of SCD symptoms. Southwestern Province
patients, on the other hand, are the carriers of the typical
HBB African-derived haplotypes with lower levels of HbF. In
addition, they exhibit lower incidences of ischemic brain injury,
priapism, leg ulcers and increased incidences of splenomegaly
in comparison with African Americans phenotype. This
difference has been attributed to variation in levels of HbF or
joint occurrence of a-thalassemia (Akinsheye et al., 2011).1.2.2. Co-inheritance of a-thalassemia
a-Thalassemia is a form of genetic blood disorder in which
there is impaired production of alpha globin chains of
hemoglobin, eventually resulting in anemia. One in three
persons with SCD from the American black population carries
a-thalassemia variant with different complications. In people
of African descent, there often exists heterozygosity or homo-
zygosity for the deletion of the a-globin gene. a-Thalassemia
regulates sickle cell anemia by reducing the rate of polymeriza-
tion, thereby lowering intracellular concentrations of HbS.
The hematologic and laboratory variations observed clinically
in SCA-a-thalassemia patients include increased hemoglobin
concentration, lower mean corpuscular volume (MCV), lower
reticulocyte count, elevated HbA2, lower bilirubin levels, fewer
aggregated and irreversibly-sickled cells, increased erythrocyte
lifespan, and almost no change in HbF concentration. The
extent of these changes is linked to the number of deleted
a-globin genes (Steinberg, 2009). The beneﬁts and liabilities
associated with the presence or absence of a-thalassemia in
SCA are most probably due to the effects of a-thalassemia
on cell hemolysis. Some associations of a-thalassemia and
the clinical features of sickle cell anemia are summarized in
Table 1:
1.3. Biomarkers used for red blood cell dehydration
RBCs in SCD are typiﬁed by bizarrely increased cation perme-
ability and cations loss which causes RBC dehydration, and
increases the rate of Hb polymerization. To assess the cation
loss, fresh blood and radioactive isotopes are needed, hence
making it difﬁcult to use as routine biomarker. However, indi-
rect markers of RBC dehydration are measurement of irrevers-
ibly sickled cells (ISCs) on the blood ﬁlm as well as
measurement of red cell density (Ellory et al., 1998).
ISCs exist in the form of elongated, sharpened-end cells
with cell axial ratio (length divided by width) close to 2. Even
when fully oxygenated, the ISCs tend to maintain their atypi-
cal shape. Studies have found no signiﬁcant relationship
among the numbers of ISCs with acute complications
(Rodgers et al., 1985). Those RBCs were observed as a wet
preparation when imaged with phase contrast microscopy.
Clinical biomarkers in sickle cell disease 27Likewise, high density gradient centrifugation or cytometry is
used as a biomarker for red cell density. Some studies have
suggested that the increase in pain is associated with higher
number of dense red cells (Ballas and Smith, 1992).
1.4. Biomarkers for red cell adhesion
Structural asymmetry of RBC membrane, which is maintained
normally, is lost in SCD, causing the exposure of erythrocyte
phosphatidylserine and phosphatidylethanolamine as revealed
by ﬂow cytometry analysis. In typical SCD, vascular occlusion
is initiated by adhesion of circular reticulocytes to vascular
endothelium. This leads to a cascade of painful crisis ending
in organ failure. At least two receptors, usually present on ret-
iculocytes, appear to be important in this adhesion process.
The CD36 (Glycoprotein IV) is implicated in the binding of
RBCs to endothelial lining of blood vessels by its binding to
thrombospondin (Kaul et al., 2009). Likewise, the binding of
integrin a4b1 (very late activation antigen-4) to vascular cell
adhesion molecule-1 (VCAM-1) and ﬁbronectin occurs on
the endothelial lining of blood vessels. Flow cytometry studies
have revealed that the expression of CD36 and integrin a4b1 is
reduced on the reticulocytes of SCD patients when hydroxy-
carbamide is used, which may be a way to monitor therapeutic
beneﬁts. However, hereditary nonexistence of CD36 receptor
has not been shown to change the manifestation of SCD, thus
decreasing the value of red cell adhesion as a biomarker (Lee
et al., 2001).
1.5. Biomarkers for white cell adhesion
Some studies have demonstrated that the incidences of acute
pain in SCD patients increase when there is a heightened
expression of certain leukocyte adhesion molecules such as
L-selectin and aMb2 (Okpala et al., 2002). This suggests that
some white cell adhesion molecules can serve as biomarkers.
1.6. Biomarkers for inﬂammation
Increasing amount of experimental evidence suggests a close
connection between chronic inﬂammatory processes and sickle
cell disease (SCD) (Platt, 2000). Many markers of inﬂamma-
tion are increased in SCD and they may have clinical value
as biomarkers. These markers of inﬂammation include.
1.6.1. Total white cell count
SCD is characterized by abnormally elevated total white cell
count, secondary to hyposplenism and inﬂammation. Unusu-
ally high white cell count in SCD may be prognostic of condi-
tions of clinical severity such as brain infarcts, acute chest
syndrome and death. However, those SCD patients taking
hydroxycarbamide show evidence of decreased white cell count
and reduced frequency of acute pain (Charache, 1997).
1.6.2. C-reactive protein (CRP)
C-reactive protein (CRP) is found in the plasma. It is the most
commonly assessed marker of acute and chronic inﬂammation.
Acute chest syndrome (ACS) manifests in SCD patients when
there is an increase in CRP levels due to vaso-occlusion, hence
blocking the blood ﬂow to organs and causing vaso-occlusion
crisis (Bargoma et al., 2005). Krishnan et al. have also reporteda strong link between high sensitivity C-reactive protein
(hs-CRP) and vaso-occlusion in pediatric SCD patients
(Krishnan et al., 2010).
1.6.3. Erythrocyte sedimentation rate (ESR)
The erythrocyte sedimentation rate (ESR) is the rate at which
RBCs sediment or settle in a period of 1 h. ESR is a non-
speciﬁc measure of inﬂammation. In SCD patients, the inter-
pretation of ESR is complicated due to their low hematocrit
values, which tends to give higher ESR values. This is further
complicated by the fact that sickle erythrocytes fail to form
rouleaux, which results in lower ESR values. This problem
can be partially circumvented by increasing the reproducibility
of this assay by repeated measurements in individual patients
in order to observe inﬂammation processes. However, estab-
lished normal ranges may still not apply in the case of SCD
patients (Eastman, 1984).
1.6.4. Secretory phospholipase A2 (sPLA2)
The enzyme secretory phospholipase A2 (sPLA2) cleaves phos-
pholipids and generates fatty acids (such as arachidonic acid)
leading to a cycle of inﬂammatory events. It has been reported
in a clinical study that elevated levels of sPLA2 are detected in
ACS patients 24–48 h before the clinical diagnosis of ACS. It
was shown that increased levels of sPLA2 can predict impend-
ing ACS in patients with sensitivity reaching up to 100% and
speciﬁcity as high as 67% (Styles et al., 2000). Likewise, it has
been shown in a small sample randomized, clinical trial blood
transfusion lowered sPLA2 levels and prevented ACS in SCD
patients, suggesting that sPLA2 can serve as a useful
biomarker (Field et al., 2009; Styles et al., 2007).1.6.5. Other inﬂammatory markers
The inﬂammatory nature of SCD is further conﬁrmed in stud-
ies which measured other biomarkers such as elevated levels of
interleukins (IL2, IL3, IL6, IL8 and IL10), urinary cysteinyl
leucotriene E4 (28), and serum levels of prostaglandin-E2,
CA 15-3, soluble CD40 ligand, HSP-70, ferritin, angiopoietin
1 and 2, stromal derived factor 1, tumor necrosis factor-a
and tumor necrosis factor receptor-1 (Eastman, 1984).
2. Biomarkers for hemolysis
2.1. Hemoglobin concentration
Low hemoglobin is the solitary most useful biomarker in SCD.
It is generally associated with unpredictable future clinical out-
comes of SCD (Kato et al., 2006) with higher risk for medical
problems most important of which is stroke either due to cere-
bral hemorrhage or cerebral infarction (Gueguen et al., 2014),
premature death (Andemariam et al., 2014), abnormal trans-
cranial Doppler (TCD) velocities (Rees et al., 2008), and high
tricuspid regurgitant jet (TRJ) velocity (Gladwin et al., 2004).
2.2. Direct measurement of RBC survival
The typical RBC survival in SCD is 15–17 days with high var-
iability in this range (Hebbel, 2011). Direct measurement of
RBC survival by chromium-53 labeling is not feasible for
regular clinical use. Nevertheless, biotin labeled RBC is more
28 G.A. Damanhouri et al.useful after proper standardization of the assay (Mock et al.,
2011).
2.3. Reticulocyte count
Reticulocyte count correlates well with RBC life span and is a
routine procedure in automated blood cell counters. However,
it is not clear whether it gives any additional information over
total Hb values (Hebbel, 2011).
2.4. Serum lactate
Serum lactate dehydrogenase (LDH-1) levels increase in SCD
patients with leg ulcers, priapism, and TRJ and TCD veloci-
ties. Although it is the total LDH that is measured in clinical
practice, it has been observed that other LDH isoenzymes
found in the brain, liver and muscle are reduced in SCD
(Kato et al. 2006; O’Driscoll et al., 2008). LDH levels also tend
to increase in erythropoiesis with premature death of RBCs
and other cellular events which involve increased incidences
of apoptosis. However, it remains ambiguous as to whether
elevated levels of LDH are indicative of SCD pathology or it
is just the outcome of increased anemia. Aspartate transami-
nase has similar prognosis as a biomarker in SCD, although
not routinely used (Rees et al., 2008).
2.5. Haptoglobin
Almost all individuals with SCA have low levels of haptoglo-
bin and this may not have any medical relevance (Moller
et al., 2011). Under normal physiological conditions, free
plasma hemoglobin can easily bind to haptoglobin and the
levels of haptoglobin are undetectable under such conditions.
On the other hand, due to the presence of intravascular hemo-
lysis, the haptoglobin molecules are saturated and plasma
hemoglobin levels are elevated in SCD. Measurements are
technically challenging due to the sensitivity limits of the test
involving extremely fresh blood sample. This is further compli-
cated by the fact that it is exactly not apparent if what is being
measured includes haptoglobin–hemoglobin complexes, hae-
mopexin–haem complexes, or methemalbumin/hemoglobin in
those microparticles (Kato et al., 2006). Although free plasma
hemoglobin levels correlate with LDH (Hebbel, 2011), the use
of haptoglobin as a clinical marker is still not documented.
3. Biomarkers of hypercoagulability
Hypercoagulability refers to the tendency to form blood clot
inside a blood vessel and obstructing the blood ﬂow due to cer-
tain inherited or acquired disorders. Hypercoagulability in
SCD is complex with many factors involved in it. SCD patients
exhibit elevated plasma levels of thrombin generation markers,
abnormal activation of the ﬁbrinolytic system, depletion of
natural anticoagulant proteins and increased tissue factor
expression, even in the non-crisis, stable condition of SCD
(Ataga and Key, 2007). The process of coagulation is activated
when there is enhanced exposure of membrane erythrocyte
phosphatidylserine and erythrocyte phosphatidylethanolamine
as well as enhanced circulating microparticles originating from
numbers of erythrocytes, endothelial cells, white blood cellsand platelets (Shet et al., 2003). Tissue factor expression on
endothelial lining of blood vessels is induced by free haem.
In addition, platelet activation is also enhanced during this
process (De Franceschi et al., 2011). To prove that monitoring
hypercoagulability is beneﬁcial for clinical purposes needs fur-
ther studies. CRP levels are always abnormally high in individ-
uals with SCD and this information alone is not sufﬁcient in
the diagnosis of venous thromboembolism. Thrombosis has
not been studied extensively in the clinical settings and the
few studies that have been conducted on thrombosis claim that
SCD represent a lesser degree of thrombophilia in which the
prevalence of venous thromboembolism may not be enhanced
(Stein et al., 2006). Currently there are no compelling reports
demonstrating an association between the occurrences of
vaso-occlusive complications and blood coagulation markers.
Likewise, no studies to date have shown any clinical advanta-
ges of anticoagulant or antiplatelet therapies, even though
there is a need to conduct randomized, clinical trials to demon-
strate any beneﬁts of such therapies (Eastman, 1984).
4. Biomarkers for oxidative stress
Oxidative stress appears to contribute to the pathophysiology
of SCD. SCD has been linked with biological processes such as
inﬂammation, vasculopathy, hemolysis, infection, vaso-occlu-
sion, and reperfusion injury (Nur et al., 2011b). Therefore,
SCD patients at high risk of oxidative damage can be identiﬁed
by the use of biomarkers for oxidative stress. This can also
help in the management of treatments involving the use of
zinc, N-acetylcysteine, and vitamin supplements especially C
and E (Jones, 2002).
Reduced glutathione (GSH) is a major tissue antioxidant.
In the event of cells exposed to increased oxidative stress,
GSH changes to oxidized glutathione (GSSH) and, hence,
the ratio of GSH/GSSG decreases. In SCD patients, GSH lev-
els as well as GSH/GSSG ratio are decreased (Stein et al.,
2006; Moller et al., 2011). Therefore, measurement of GSH
levels may serve as a useful biomarker of in vivo oxidative
stress (Jones, 2002; Ashfaq et al., 2006). In addition, GSH
and glutamine concentrations are among the indirect markers
to assess the oxidative assault on tissues and cells in disorders
such as SCD (Morris et al., 2008).5. Biomarkers for vasculopathy and endothelial dysfunction
Stroke, pulmonary hypertension and renal disease are
recognized as the most important complications of vasculopa-
thy and endothelial dysfunction. The direct markers of vascu-
lopathy depend on evaluation of the type and role of the
vascular system by employing the ultrasound-based technique
using ﬂow-mediated endothelium-dependent dilatation (de
Montalembert et al., 2007). Identiﬁed biomarkers for endothe-
lial dysfunction which are abnormal in SCD patients are given
as follows.
5.1. Triglycerides
Pediatric patients with SCD exhibit high triglyceride levels,
which correlate considerably well with markers of hemolysis,
such as LDH and FMD (Zorca et al., 2010).
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SCD patients show diminished levels of apolipoprotein A-1 as
identiﬁed by proteomic analysis when compared with same
gender, healthy controls (0.98 g/L vs. 1.33 g/L, P< 0.001)
(Yuditskaya et al., 2009).
5.3. Vascular endothelial growth factor (VEGF)
SCD is also characterized by elevated levels of VEGF, a mar-
ker indicating blood vessel damage and hypoxemia. Moreover,
increased levels of VEGF correlate well with many other bio-
markers signifying other problems such as hemolysis, inﬂam-
mation and enhanced TRJ velocity (Ashfaq et al., 2006).
5.4. Placental growth factor (PGF)
PGF is produced by placental and erythropoietic tissue,
particularly during embryogenesis. PGF plays a pivotal role
in angiogenesis and activation of monocytes. SCD is char-
acterized by elevated blood concentrations of PGF during
steady-state with subsequent increase during the episodes
of acute pain and/or during complications arising from
pregnancy in SCD women. PGF can serve as an important
biomarker linked with pregnancy in SCD (Brittain and
Parise, 2007).
5.5. Endothelin-1
Endothelin-1 (ET-1) is a protein that is found in endothelial
cells and also in other cell types. The presence of ET-1 and its
receptors in neurons is an indication of its potential role as a
neurotransmitter and neuromodulator. Studies utilizing exoge-
nous ET-1 have demonstrated that pain transmission is inﬂu-
enced by ET-1 (Eastman, 1984). In SCD patients, the levels
of ET-1 rise with simultaneous increase in the intensity of pain.
However with hydroxycarbamide treatment, ET-1 levels
decrease with decrease in pain (Lapoumeroulie et al., 2005).
6. Biomarkers of damage to speciﬁc organs
6.1. Bone disease
The most relevant clinical biomarkers to bone disease are Vita-
min D and alkaline phosphatase. Low levels of Vitamin D are
characteristically seen in pediatric SCD patients whereas
increased alkaline phosphatase levels are observed with growth
(Chapelon et al., 2009). Acute bone disease in SCD happens
with vaso-occlusion and osteomyelitis whereas chronic bone
disease occurs in the event of avascular necrosis of the hips
and shoulders. The two biomarkers of bone turnover pyridino-
line and deoxypyridinoline are composed of cross-linked
collagen ﬁbers. Urinary levels of both pyridinoline and deoxy-
pyridinoline are elevated in asymptomatic SCD and these levels
rise even further in the events of acute pain (Nebor et al., 2010).
6.2. Cardiac disease
Cardiac disease is considered unusual in SCD. However,
cardiovascular problems in SCD patients have been shownto contribute to more than 15% of adult deaths (Gladwin
et al., 2004).
6.3. Tricuspid regurgitant jet velocity (TRV)
Increased tricuspid regurgitant jet velocity (TRV) is linked to
higher incidences of unexplained deaths in young adult SCD
patients with cardiopulmonary complications (Machado
et al., 2006).
6.4. NT-pro brain natriuretic peptide (NT-proBNP)
N-terminal prohormone of brain natriuretic peptide
(NT-proBNP) is a protein generated by the heart and it is
found in higher levels in patients suffering from congestive
heart failure and pulmonary hypertension. NT-proBNP can
also serve as a biomarker for SCD patients because its levels
are elevated in those patients (Machado et al., 2006).
6.5. Cardiac troponin I
Cardiac troponin I levels are elevated in SCD individuals
going through ACS, which is also accompanied with high TRV
and increased death rates (Mekontso-Dessap et al., 2008).
6.6. Hyposplenism
Spleen is one of the initial organs damaged in SCD. The gold
standard for assessment for splenic ﬁltration function is a
99mTc sulfur-colloid liver spleen (LS) scan but it requires radi-
ation. Pitted erythrocyte (PIT) and Howell–Jolly Bodies
(HJBs) have been assessed as a better non-invasive biomarker
for spleen function (Rogers et al., 2011).
6.7. Pitted RBC counts
Pitted RBCs are normally removed by healthy spleen. How-
ever, in the ﬁrst year of their lives among SCD patients, more
than 3.5% RBCs have pits, which is a sign of splenic dysfunc-
tion. Higher percentage of pitted RBCs before reaching the age
of one year is a clinical indicator of unfavorable outcomes in
the future (Miller et al., 2000). Hence, high numbers of pitted
RBC counts may implicate splenic impairment. The procedure
of pitted RBCs count is slow and laborious, requiring ﬁxed
RBCs to be analyzed under phase-contrast microscopy.
6.8. HJBs by ﬂow cytometry
The presence of HJBs has been associated with hyposplenism.
Measuring the levels of HJBs is a quick way of testing spleen
function, and it is strongly linked with pitted RBC counts. This
assay is currently offered by very few laboratories (Rogers
et al., 2011).
6.9. Renal dysfunction
Kidney damage is the unavoidable outcome of SCD. Biomark-
ers for renal function in SCD are well established. The most
routinely used biomarkers are blood urea nitrogen, creatinine
concentration, urine albumin to creatinine ratio, etc. Renal
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ning with glomerulus hyperﬁltration and ending in kidney fail-
ure in 30% of patients (De Franceschi et al., 2011). Micro
albuminuria is common in childhood but it may continue to
exist in 20% of adults with SCD in the form of nephritic range
protein loss, with more than 3.5 g protein urea in 24 h
(Scheinman, 2009). Asymptomatic hematuria is considered as
one of the most prevalent features of sickle cell nephropathy.
Prior to conﬁrming the diagnosis of sickle cell nephropathy,
other causes of renal dysfunction should be ruled out (58).
6.10. Pulmonary dysfunction
Major pulmonary dysfunction in children with SCD comprises
of acute chest syndrome and bronchial hyperactivity
(Eastman, 1984). The biomarkers associated with this condi-
tion are increased white blood cell counts (Maitre et al.,
2000) and raised secretary phospholipase A2 levels (Styles
et al., 1996).
7. Conclusion
SCD is characterized by a wide variety of abnormal levels of
biomarkers that have been identiﬁed and associated with dif-
ferent pathological conditions. With the exception of a few,
none of the biomarkers provide prognostic information
regarding the management of the disease. Currently, measur-
ing the hemoglobin values, HbF levels, reticulocytes counts
and WBC counts are the primary diagnostic tools for the man-
agement of SCD. Extensive clinical trials are required to iden-
tify unambiguous independent markers for the corresponding
pathological conditions of SCD. Existing information about
biomarkers in SCD is still in its incipient stage and the future
holds many challenges (Eastman, 1984).
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